This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cleveland BioLabs Strengthens Clinical Development Team

BUFFALO, N.Y., April 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the appointment of key clinical development and regulatory affairs executives to optimally position the company for successful development of its drug candidates. Jean Viallet, M.D., has joined the Company as Chief Development Officer, reporting to the Chief Executive Officer, and will be responsible for overseeing CBLI's clinical strategy, trials and operations, regulatory affairs and preclinical development. The Company also announced the appointment of Gillian Miller, Ph.D., as Senior Director of Regulatory Affairs and Judith Schnyder, MBA as Director of Clinical Operations.

Dr. Viallet brings more than 20 years of experience as a medical oncologist and senior executive at both large and small pharmaceutical companies. Most recently, Dr. Viallet established Viallet Oncology Consulting, LLC after serving as the Chief Medical Officer of Precision Therapeutics, Inc. Prior to this he guided clinical and preclinical development at Gemin X Pharmaceuticals, Inc., as their Executive Vice President and Chief Medical Officer, culminating in a successful strategic acquisition of Gemin X by Cephalon, Inc. Before joining Gemin X, Dr. Viallet held senior clinical oncology development positions at GlaxoSmithKline PLC and Sanofi. He has extensive experience with all phases of drug development and has been involved in multiple successful Investigational New Drug applications, New Drug Applications, Biologics License Applications, European Medicines Agency submissions and U.S. Food and Drug Administration Advisory Committees. Dr. Viallet has also served in several clinical and academic posts at Hospital Notre Dame, Montreal General Hospital, McGill University and the Universite de Montreal. 

Dr. Viallet noted, "As a clinical oncologist and scientist, I am grateful for the opportunity to guide CBLI's drug candidates derived from world-class science into established therapeutic advances for cancer patients and victims of potentially lethal radiation exposure. The company's spirit of innovation, their commitment to developing breakthrough treatments for oncology and acute radiation syndrome and the promising 'trial-ready' drugs in their pipeline are what attracted me to CBLI."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs